New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLivagen vs Melanotan 1

Livagen vs Melanotan 1

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Livagen
Skin & CosmeticSexual Health & Libido
Melanotan 1
Summary
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
Melanotan 1 (Afamelanotide) is a synthetic analog of α-MSH that selectively stimulates melanogenesis (tanning) through MC1R activation. It provides UV-independent skin pigmentation and is FDA/EMA-approved under the name SCENESSE for erythropoietic protoporphyria (EPP) and vitiligo.
Half-Life
Short (minutes); gene-regulatory effects are sustained
~40–60 minutes (free peptide); implant formulation (SCENESSE) releases over months
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
0.5–1 mg
Frequency
Daily for 10–30 days
Daily until desired color achieved, then maintenance
Key Benefits
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
  • Induces skin pigmentation/tanning without UV exposure
  • Provides photoprotection in photosensitivity conditions (EPP)
  • FDA-approved for erythropoietic protoporphyria (SCENESSE)
  • Approved in EU for EPP treatment
  • Anti-inflammatory via MC1R
  • Mild libido enhancement
  • Potential skin cancer prevention through melanin protection
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
  • Nausea (especially at higher doses)
  • Facial flushing
  • Fatigue
  • Injection site reactions
  • +3 more
Stacks With